The survival benefit from ICIs was similar in patients with and without brain metastases in the following subgroups: immune monotherapy, NSCLC, subsequent line settings, median follow-up > 20 months, and targeting PD-L1. Here, CD274 is linked to non-small cell lung carcinoma.